EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparison of the effectiveness, safety and tolerability of Perampanel and Levetiracetam as monotherapy in Chinese patients with focal‐onset seizures: A single‐center, ambispective, open‐label, real‐world observational study

Haiyan Ma iD, Rui Zhang iD, Yan Zhang, Honghao Xu, Xuefeng Qu, Yiqing Yang, Jiajia Li, Lu Yang iD, Qigang Zhou iD, Haitao Zhu iD

Epilepsia Open · 2026

DOI: 10.1002/epi4.70147 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Epilepsia Open, 2026. Verfasst von Haiyan Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epilepsy Center, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Anticonvulsants, Levetiracetam, Epilepsies, Partial, Seizures. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Nanjing Medical Science and Technology Development Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare the effectiveness and safety of Perampanel (PER) and Levetiracetam (LEV) as monotherapy in Chinese patients with focal‐onset seizures (FOS).

Methods

This is a single‐center, ambispective, open‐label, real‐world observational study. The PER arm of the study prospectively enrolled patients aged ≥4 years with FOS who visited Nanjing Brain Hospital during January 2020 to December 2021. These patients received PER monotherapy and were prospectively followed until January 2024. For the LEV arm, data were retrospectively collected from patients with FOS who started LEV monotherapy during January 2019 to December 2021, and these patients were retrospectively followed until January 2024. The primary endpoint was seizure‐freedom rate (SFR) after 24 months of treatment. Treatment‐emergent adverse events (TEAEs) were recorded.

Results

Seventy patients in the PER group and 77 patients in the LEV group were enrolled. The PER group had a non‐significant trend of higher SFR than the LEV group at 24 months (58.6% vs. 41.3%, p = 0.06). At 6 and 12 months, PER showed significantly higher SFRs than LEV (69.8% vs. 48.6%, p = 0.01; 68.3% vs. 38.8%, p < 0.001, respectively). The two groups had comparable retention rates. The PER group had a significantly higher incidence of TEAEs than the LEV group (37.1% vs. 11.7%, p < 0.001) because of the significantly higher incidence of dizziness in the PER group. None of the TEAEs was serious. Significance Patients with FOS receiving PER monotherapy were more likely to achieve seizure freedom and had a higher incidence of dizziness than those receiving LEV monotherapy. Plain Language Summary This study compared the effectiveness and safety of PER and LEV as monotherapy in Chinese patients with focal‐onset seizures (FOS), in which 70 patients receiving PER monotherapy and 77 patients receiving LEV monotherapy were enrolled. Compared with LEV, PER had significantly higher seizure‐freedom rates (SFRs) at 6 and 12 months and a non‐significant trend of higher SFR at 24 months. The two treatments had comparable retention rates. Chinese patients with FOS receiving PER monotherapy were more likely to achieve seizure freedom and had a higher incidence of dizziness than LEV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsLevetiracetamEpilepsies, PartialSeizuresPyridonesHumansMaleFemaleAdultMiddle AgedTreatment OutcomeNitrilesRetrospective StudiesChinaProspective StudiesAgedEast Asian People

Stichwörter der Autor:innen

Chinese patientsLevetiracetam monotherapyPerampanel monotherapyfocal‐onset seizuresseizure‐freedom rate

Substanzen

perampanelAnticonvulsantsLevetiracetamNitrilesPyridones

Autor:innen und Institutionen

  • Department of Epilepsy Center, Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, China.
  • Department of Clinic Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China.
  • The Key Center of Gene Technology Drugs of Jiangsu Province, Nanjing Medical University, Nanjing, Jiangsu, China.

ORCID-Profile: Haiyan Ma, Rui Zhang, Lu Yang, Qigang Zhou, Haitao Zhu

Förderung

  • Nanjing Medical Science and Technology Development Project

Zitieren

APA

Ma, H., Zhang, R., Zhang, Y., Xu, H., Qu, X., Yang, Y., Li, J., Yang, L., Zhou, Q., & Zhu, H. (2026). Comparison of the effectiveness, safety and tolerability of Perampanel and Levetiracetam as monotherapy in Chinese patients with focal‐onset seizures: A single‐center, ambispective, open‐label, real‐world observational study. Epilepsia Open. https://doi.org/10.1002/epi4.70147

Vancouver

Ma H, Zhang R, Zhang Y, Xu H, Qu X, Yang Y, et al. Comparison of the effectiveness, safety and tolerability of Perampanel and Levetiracetam as monotherapy in Chinese patients with focal‐onset seizures: A single‐center, ambispective, open‐label, real‐world observational study. Epilepsia Open. 2026. doi:10.1002/epi4.70147

BibTeX
@article{Ma2026,
  author = {Ma, Haiyan and Zhang, Rui and Zhang, Yan and Xu, Honghao and Qu, Xuefeng and Yang, Yiqing and Li, Jiajia and Yang, Lu and Zhou, Qigang and Zhu, Haitao},
  title = {Comparison of the effectiveness, safety and tolerability of Perampanel and Levetiracetam as monotherapy in Chinese patients with focal‐onset seizures: A single‐center, ambispective, open‐label, real‐world observational study},
  journal = {Epilepsia Open},
  year = {2026},
  doi = {10.1002/epi4.70147}
}
Kostenlos starten →